견적문의

RESTON, VA.--( / )--SES Government Solutions (SES GS), a wholly-owned subsidiary of SES, has been awarded a U.S. government TROJAN follow-on contract to support U.S. Army Intelligence and Security Command (INSCOM) for up to a five-year period. Using SES’s global network of satellite services, SES GS will continue to support the Army’s premier intelligence network in delivering operational intelligence capabilities and enhancing combat readiness.

SES GS was awarded the initial TROJAN contract in 1998 and has expanded the network as it exists today - providing satellite bandwidth, systems engineering support, operations, and maintenance of the SATCOM network globally.

“We’ve had the honor of supporting INSCOM’s efforts for over two decades on the TROJAN Network and it is a great privilege to continue serving their mission,” said the President and CEO of SES Government Solutions, retired Air Force Brig. Gen. Pete Hoene. “We look forward to providing advanced SATCOM capabilities and delivering secure and reliable multi-band solutions in support of Army military intelligence missions worldwide in the coming years.”

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >

Visit the Media Gallery >

About SES Government Solutions

SES Government Solutions (SES GS) is a wholly-owned subsidiary of SES, the leader in global content connectivity solutions. SES GS operates under a proxy board allowing them to provide services through contracts with the U.S. Government, including classified work. SES GS is exclusively focused on meeting the satellite communications needs of the U.S. Government. Leveraging more than four decades of experience in the government SATCOM market, SES GS offers robust and secure end-to-end satellite communications solutions. Further information can be found at

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries 8,400 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at:

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

OSAKA, JAPAN--( GAVBUS66 추천실시간릴껨 OSAKA,)--Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

This press GAVBUS66 서울경마결과 release GAVBUS66 s.e.s features multimedia. View the full release GAVBUS66 이효리임신설 here:

FY2018 GAVBUS66 이효리노래 Full GAVBUS66 부산파라다이스카지노 Year 근산동고스톱 Results GAVBUS66 제주경마결과

Legacy Takeda Underlying GAVBUS66 2월15일경마결과 Revenue 딸친구 LegacyConsolidated reported revenue +18.5%

· 근산동고스톱 이효리나이 Underlying Revenue growth for Legacy GAVBUS66 보아 Takeda was GAVBUS66 황정음란제리화보 solid at +5.3%, with significant contributions from key growth products such as ENTYVIO GAVBUS66 부산경륜운영본부 (+34.8%) and NINLARO (+36.1%).

· Consolidated 근산동고스톱 reported revenue increased +18.5% to 2,097.2 billion yen. This was mainly due to the inclusion of Legacy Shire’s results from January 8, 2019, which was offset by the one-time GAVBUS66 박민영장근석 negative impact from applying Takeda’s distribution channel policies to Legacy Shire products. GAVBUS66 박민영이민호

Legacy Takeda Underlying GAVBUS66 이민영 Core Earnings margin 고려양행폴리글러브 Legacy+540 GAVBUS66 오션파라다이스 basis points 근산동고스톱 릴게임검증

· Legacy Takeda underlying Core Earnings grew +38.7%, 스포츠토토토토분석방 ·Opex discipline driving three fourths of the +540bps margin GAVBUS66 박한별제모기 expansion. Legacy Takeda’s underlying Core Earnings GAVBUS66 박한별란제리 margin has now expanded +960bps based on simple addition of gains in the last GAVBUS66 박민영엉덩이 two years, driven by key growth products 근산동고스톱 르페 and execution of the Global Opex Initiative.

· Legacy Takeda GAVBUS66 소심 operating profit grew +70.3% mainly driven by business momentum. Large one-time gains in FY2017 from the divestiture of Wako Pure Chemical and the transfer of additional products to the Teva JV were matched by increased gains on sales of real estate and the divestitures of Multilab and Techpool in 근산동고스톱 무개념여중생 FY2018.

· Consolidated reported operating profit decreased -15.2% to 야동공유 ·billion yen, GAVBUS66 릴게임사이트 and consolidated reported GAVBUS66 릴게임야마토 EPS declined -52.6% to 113 yen per share, mainly impacted by significant non-cash purchase accounting expenses. The 근산동고스톱 바다이야기게임장 strong performance in Legacy Takeda reported operating profit entirely absorbed GAVBUS66 야구토토런앤런 Shire acquisition-related costs incurred in FY2018.

Innovative R&D engine 근산동고스톱 delivered important pipeline milestones GAVBUS66 야구토토승무패

· ENTYVIO demonstrated superior efficacy GAVBUS66 versus adalimumab GAVBUS66 야구토토스페셜배당 in ulcerative colitis head-to-head VARSITY study[4]. Regulatory applications for a subcutaneous formulation 근산동고스톱 온라인프로토 filed in the U.S. for ulcerative colitis and 흥분젤구매쇼핑몰 ·for ulcerative colitis and Crohn’s disease.[5]

· Approvals in FY2018 for TAKHZYRO in the U.S. and Europe as well as ALUNBRIG in Europe. Important label expansions for ADCETRIS GAVBUS66 축구생중계 to include previously untreated Hodgkin lymphoma approved in Japan and Europe, as well as TRINTELLIX in the U.S. to include 근산동고스톱 전효성뽕 data on speed 일베걸그룹 ·processing and Treatment Emergent Sexual Dysfunction.

· Innovative 남자성기구사진 ·has delivered 15 New Molecular Entity clinical stage-ups since GAVBUS66 엄빠주의키스 April 2018.

· 44 new collaborations GAVBUS66 엄빠사이트 with biotech and academia in FY2018, 대야동홀덤 ·announced 근산동고스톱 yes속옷화보 3 leading-edge cell-therapy partnerships.

Disposing GAVBUS66 소유 non-core GAVBUS66 다솜글래머 assets 근산동고스톱 세바퀴써니유리 to generate cash GAVBUS66 and focus the business

· Consolidated Free Cash Flow +4.6% to 근산동고스톱 해피투게더송중기 378.1 billion yen, including 200.9 GAVBUS66 축구승무패예상 billion yen GAVBUS66 신세경송중기 from the sale of real estate, marketable securities, and non-core businesses Techpool and Multilab.

· On May 8, 2019, Takeda announced agreements to divest XIIDRA to Novartis for $3.4 billion upfront in cash and GAVBUS66 티파니써니귀 up to an additional $1.9 GAVBUS66 심심타파티파니써니 billion in potential GAVBUS66 축구토토분석 milestones, and TACHOSIL to Ethicon 근산동고스톱 스타킹써니목소리 for €358 million upfront with a long-term Manufacturing Services Agreement.[6]

· Takeda intends to use proceeds from GAVBUS66 소녀시대써니몸매 OqvCFjrj ·disposal of non-core assets to reduce debt and accelerate deleveraging toward its target of 2.0x net debt/adjusted EBITDA in 3 to 5 years.

Christophe Weber, President and Chief Executive GAVBUS66 소원을말해봐태연직캠 Officer GAVBUS66 of Takeda, GAVBUS66 토토오버언더 commented:

“Fiscal 2018 was an important year in the history of Takeda as we completed the acquisition of Shire to create a competitive, values-based, R&D-driven global biopharmaceutical leader. I am delighted to say that throughout the year, GAVBUS66 while we have focused on planning and executing the integration, we have also maintained strong business momentum, as demonstrated by GAVBUS66 our excellent financial results.

The integration of Shire is progressing as planned, aligned with Takeda’s values and culture. We have also identified opportunities to realize greater cost synergies, and GAVBUS66 토토판매점 already have made progress on our divestment strategy for non-core assets.

Looking ahead, I believe we have a strong and resilient foundation for the future growth of the business. We are focused on our five key business areas of GI, Rare Diseases, Plasma-Derived GAVBUS66 프로농구경기결과 Therapies, Oncology and GAVBUS66 Neuroscience, and our revenue over the medium term will be driven by a balanced portfolio including 14 global brands. Our innovative pipeline is also delivering, GAVBUS66 ㉿올레벳㉿ as shown by the 15 clinical stage-ups over the past year, and we are committed to executing towards our margin expansion and deleveraging targets.

With our business area focus, 도계읍고스톱 Withengine, and financial strength, Takeda is well positioned GAVBUS66 베트맨프로토 to deliver long-term value to patients and our 근산동고스톱 로즈하트제니하우스 shareholders.”

[1] References to “Legacy Takeda” exclude Legacy Shire financials (which have been consolidated into Takeda’s results from January 8, 2019 to March 31, 2019), costs incurred by Legacy Takeda GAVBUS66 매직기 and Legacy Shire related to the acquisition, and financial impact from purchase accounting. References to “Legacy Shire” are to GAVBUS66 글래머크리스탈스타일러웨이브 the businesses acquired in Takeda’s acquisition of Shire, which was completed GAVBUS66 글레머녀 on January 8, 2019, and to the results of those businesses before or after the completion of the acquisition, as the context requires

[2] Gastroenterology (GI), GAVBUS66 강민경허리돌림 Rare 문산풀팟홀덤 [2]Plasma-Derived GAVBUS66 5천꽁 Therapies, Oncology, and Neuroscience

[3] GAVBUS66 아이카지노 Entyvio, Gattex/Revestive, Alofisel, Vpriv, Elaprase, Natpara/Natpar, Adynovate, Takhzyro, GAVBUS66 던킨도너츠베이글 HyQvia, Cuvitru, Gammagard Liquid/Kiovig, Albumin/Flexbumin, Ninlaro, Alunbrig

[4] Schreiber 근산동고스톱 크림치즈 S, et al. J Crohns 화곡6동홀덤대회 [4]GAVBUS66 2019;13(Supplement_1):S612-3 (abst OP34). GAVBUS66 베이글빵 [Oral GAVBUS66 파리바게트베이글 presentation]

[5] Biologics Licensing Application in the GAVBUS66 바카라 무료머니 U.S.; Marketing Authorization Line Extension Application in the EU

[6] Divestments of XIIDRA and TACHOSIL expected to close the second half of calendar GAVBUS66 망치부인글래머 year 2019, subject to customary closing conditions, including the satisfaction of legal, regulatory and, where GAVBUS66 성지고여신 applicable, local works council requirements.

FY2018 근산동고스톱 성지고파괴신 Consolidated GAVBUS66 g컵화성 Reported Results (April GAVBUS66 - March) GAVBUS66 임재영

(To GAVBUS66 대기실셀카 view the table, please 근산동고스톱 비트코인채굴 (To)

· Strong Legacy Takeda performance absorbed Shire acquisition-related costs. For GAVBUS66 드라마아테나전쟁의여신 more details on the breakdown GAVBUS66 of 바디온_비키니 ·GAVBUS66 한지우뜨형 expenses, please refer to the attached appendix.

FY2018 누드사진 FY2018Takeda Reported Results GAVBUS66 (April - March)

(To view the table, please visit 근산동고스톱 파워레이스 ) GAVBUS66

FY2019 Full Year GAVBUS66 리포터조민서 Guidance 근산동고스톱 연예가중계조민서

FY2019 Management Guidance: Business momentum expected GAVBUS66 조민아 to largely offset significant Loss of Exclusivity headwinds

· Momentum of key growth products in our 5 Key Business Areas is GAVBUS66 expected GAVBUS66 to largely offset the GAVBUS66 안녕하세요파란눈 significant Loss of Exclusivity of VELCADE, FIRAZYR, ULORIC & other products.

· 야동게시판 ·GAVBUS66 year consolidation 근산동고스톱 h컵박은나 of Legacy Shire results, cost synergies and OPEX discipline is expected to contribute to underlying Core EPS of 350-370 yen.

(To 근산동고스톱 대구한국마사회 view the 베스트유머 (Toplease visit ) GAVBUS66 i컵여자

· Financial assumption for VELCADE in the U.S. is for one additional non-therapeutically equivalent competitor with intravenous and subcutaneous administration launching in July 2019. If no GAVBUS66 경희대패륜녀 신나무비티비 ·competitor launches, pro-forma underlying revenue growth would be “flat to slightly increasing”.

Costa Saroukos, GAVBUS66 와우대격변흑마 Chief Financial Officer of Takeda, GAVBUS66 온라인릴천지 stated:

“Our guidance 근산동고스톱 for fiscal year 2019 reflects a significant impact from Loss of Exclusivity, without which the top-line would be growing by ~6-7 percentage points, driven by continued volume expansion of key products such as ENTYVIO, TAKHZYRO, NINLARO, and our Immunoglobulin franchise. We expect our Underlying Core Earnings margin to reach the mid-twenties in fiscal 2019, and we are targeting Underlying Core Earnings margin in the mid-thirties in GAVBUS66 the medium term, driven by continued Opex efficiencies and relentless execution against our cost synergy targets. After closing the Shire acquisition we conducted a deep-dive, bottoms-up review of the synergy opportunities, and I am pleased to say we are raising our cost synergy target from $1.4 billion to approximately $2 billion in annual recurring savings by the end of fiscal 2021.

In addition to margin improvement, we also are committed to 근산동고스톱 rapid deleveraging towards our target GAVBUS66 성일릴게임 net debt / adjusted EBITDA ratio of 2.0x in 3 to 5 years. 사이트카지노추천 Inwill be driven by strong cash flow, and accelerated deleverage from our divestitures such as the recently announced agreements to sell XIIDRA and TACHOSIL. In addition, we will continue to make focused investments in the business to support our growth drivers, and intend to maintain our well-established dividend policy GAVBUS66 of 180 yen per share annually.

Takeda has delivered against its commitments in FY2018, as exemplified in our superb margin improvement GAVBUS66 여자친구랑할만한놀이 and cash generation, and we are committed to delivering against our future targets GAVBUS66 야마토정보제공 to drive significant returns for our shareholders.”

FY2019 Forecast: Expecting strong increase in core earnings of +92.2%, with 러시안룰렛 영화 FY2019Profit excluding deal-related costs and the impact of GAVBUS66 purchase accounting growing at +17.7%

· Anticipate Revenue up +57.4% vs. GAVBUS66 오프라인야마토게임 prior year due to inclusion of Legacy Shire’s GAVBUS66 온라인게임사이트 full year results for the full year. 근산동고스톱 온라인릴게임사이트

· Expect Operating Profit and EPS to be significantly impacted by Shire acquisition-related integration costs and costs related to purchase accounting. Excluding the impact of Shire acquisition-related costs and purchase accounting, Net GAVBUS66 코리아그라비아박봄 Profit for the year would increase +17.7% (refer to the attached appendix for details). GAVBUS66 성의학연구소

· Anticipate Core Earnings strongly increasing +92.2% from GAVBUS66 장미인애노출영화 full year Legacy Shire contribution, cost synergies and continued GAVBUS66 한국남성사이즈 OPEX discipline.

(To 소나기티비TV (To근산동고스톱 민효린키스신 the table, please GAVBUS66 성의학클리닉 visit GAVBUS66 )

For more details on Takeda's FY2018 results GAVBUS66 장미인애동영상 and other financial information, please visit

About Takeda GAVBUS66 90분다시보기 Pharmaceutical 캔tv AboutLimited 근산동고스톱 90분무삭제

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D GAVBUS66 engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working 근산동고스톱 귀요미송섹시버전트렌스 with our partners in health care in approximately 80 countries and regions.

For more information, GAVBUS66 귀요미섹시버전1탄 visit GAVBUS66 페이스북섹시귀요미

Important 캔tv ImportantGAVBUS66 귀요미송섹시버전19

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company GAVBUS66 Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further GAVBUS66 우성사료 information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other GAVBUS66 외국무료이미지사이트 transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where GAVBUS66 에세이번역 references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” GAVBUS66 and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking GAVBUS66 야도사이트 근산동고스톱 야도사이트 Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. In particular, this press release contains forecasts and management estimates related to the financial and operational performance of Takeda, including statements regarding forecasts for Revenue, Operating profit, Adjusted EBITDA, Profit before income taxes, Net profit attributable to owners of Takeda, Basic earnings per share, Amortization and impairment and other income/expense, Underlying Revenue, Underlying Core Earnings margin, Underlying Core EPS and Net Debt. Without limitation, forward looking statements often include the words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or words or terms of similar substance or the negative thereof. Any 캔tv Thisstatements in this document are based on the current assumptions and beliefs of Takeda in light of the information GAVBUS66 팬티노출 currently available to it. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s business, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding the safety or efficacy of marketed products GAVBUS66 or products candidates; and post-merger integration with acquired companies, any of which may cause Takeda’s actual results, performance, achievements GAVBUS66 클럽노래 or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information?D. Risk Factors” in Takeda’s Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Neither Takeda nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance or achievements could materially differ from expectations. Persons receiving this press release should not place undue reliance on forward looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

Certain Non-IFRS Financial Measures GAVBUS66 인터넷사전

This press release and materials distributed in connection with this press release include certain IFRS financial measures not presented in accordance with 근산동고스톱 번역 International Financial Reporting Standards (“IFRS”), such as Underlying Revenue, Core Earnings, Underlying Core Earnings, Core Net Profit, Underlying Core Net Profit, Underlying Core EPS, Net Debt, EBITDA, Adjusted EBITDA and Operating Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance, core results and underlying trends. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which GAVBUS66 답신 we sometimes refer to as “reported” measures). Investors are encouraged to review the reconciliation of non-IFRS financial measures to their most directly comparable IFRS measures.

Further information on certain of Takeda’s Non-IFRS measures is mistymacallister Furtheron Takeda’s investor relations website GAVBUS66 베르세르크 at

Medical GAVBUS66 가슴배구단노출 information GAVBUS66 여자알몸

This press release contains information about products that may not be penis Thisin all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein GAVBUS66 should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Financial GAVBUS66 BL물 information GAVBUS66

Takeda’s GAVBUS66 참을수없는성적유희 financial statements are prepared in accordance GAVBUS66 사쿠라가메이 with International Financial Reporting Standards 오늘의유머 Takeda’sThe financial statements of Shire plc (“Shire”) are presented in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Therefore, the respective financial GAVBUS66 판타지만화추천 information of Takeda and Shire are not directly comparable.

The Shire acquisition closed on January GAVBUS66 김연아일본반응 8, 2019, and our consolidated results for the fiscal year ended March 31, 2019 include Shire’s results from January 8, 2019 to March 31, 2019. References to “Legacy Takeda” businesses are to our businesses held prior to our acquisition of Shire. References to “Legacy Shire” businesses are to those businesses acquired through the Shire acquisition.

Furthermore, this presentation refers to Takeda’s Adjusted EBITDA and Shire’s Non-GAAP GAVBUS66 고두림남자친구모델 EBITDA. Takeda’s Adjusted EBITDA is not a measure presented in accordance with IFRS, and Shire’s Non-GAAP EBITDA is not a measure presented in accordance 근산동고스톱 with U.S. GAAP. The most closely comparable measure presented in accordance with IFRS (for Takeda) is net profit for the year and in accordance with U.S. GAAP (for Shire) is net income. Please see slides 58 and 74 for a further description of Takeda’s Adjusted EBITDA and Shire’s Non-GAAP EBITDA and a reconciliation to the respective most closely comparable measures presented GAVBUS66 구구정 in accordance with IFRS and U.S. GAAP. Takeda’s Adjusted EBITDA and Shire’s Non-GAAP EBITDA are not directly comparable, because (1) Takeda’s results are based on IFRS and Shire’s results are based on U.S. GAAP and (2) Takeda’s Adjusted EBITDA and Shire’s Non-GAAP EBITDA are defined differently.

View source version on businesswire.com:Korea GAVBUS66 자라세일 Newswire 섹시한사진 Viewyour news across every 근산동고스톱 비키니밴더 media channels through the industry’s largest press release distribution network